Edmond de Rothschild Holding’s Akebia Therapeutics AKBA Stock Holding History

Edmond de Rothschild Holding’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50,000	Closed	-$51K	–	630
2024 Q2	$51K	Hold	50,000	–	–	﹤0.01%	558
2024 Q1	$91.5K	Hold	50,000	–	–	﹤0.01%	520
2023 Q4	$62K	Hold	50,000	–	–	﹤0.01%	556
2023 Q3	$57K	Hold	50,000	–	–	﹤0.01%	553
2023 Q2	$45.8K	Hold	50,000	–	–	﹤0.01%	586
2023 Q1	$28K	Hold	50,000	–	–	﹤0.01%	644
2022 Q4	$28.9K	Hold	50,000	–	–	﹤0.01%	689
2022 Q3	$16K	Hold	50,000	–	–	﹤0.01%	751
2022 Q2	$18K	Hold	50,000	–	–	﹤0.01%	735
2022 Q1	$36K	Hold	50,000	–	–	﹤0.01%	706
2021 Q4	$113K	Hold	50,000	–	–	﹤0.01%	613
2021 Q3	$144K	Hold	50,000	–	–	﹤0.01%	581
2021 Q2	$190K	Hold	50,000	–	–	﹤0.01%	536
2021 Q1	$170K	Buy	+50,000	New	+$180K	﹤0.01%	495

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Edmond de Rothschild Holding's AKBA Position: Q3 2024 in Review

Edmond de Rothschild Holding sold out of Akebia Therapeutics (AKBA) in Q3 2024, closing a stake of 50,000 shares — an estimated $51K sold.

Edmond de Rothschild Holding first reported a position in AKBA in Q1 2021 and held it in 14 quarters. The position peaked at $190K in Q2 2021. 114 funds tracked by Wall St. Rank hold AKBA as of Q3 2024.

Edmond de Rothschild Holding reported no remaining Akebia Therapeutics position as of Q3 2024 after selling out during the quarter.
Edmond de Rothschild Holding sold 50,000 Akebia Therapeutics shares in Q3 2024, an estimated $51K.
Edmond de Rothschild Holding first reported a position in Akebia Therapeutics in Q1 2021 and held it in 14 quarters.
Edmond de Rothschild Holding's Akebia Therapeutics position peaked at $190K in Q2 2021.
114 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2024.

Based on Edmond de Rothschild Holding's 13F filing for Q3 2024, filed 14 Nov 2024.